Related Experiment Videos
[Cefuroxime stability to beta-lactamases: clinical implications]
1Dipartimento di Scienze e Tecnologie Biomediche; Facolta di Medicina e Chirurgia dell'Universita dell'Aquila. Direzione Medica, Glaxo Wellcome Italia, Verona.
Le Infezioni in Medicina
|April 24, 2003
Summary
Cefuroxime remains an effective antibiotic against many bacteria, even those producing beta-lactamases. This review analyzes its use in Italy, confirming its therapeutic value against common resistant strains.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Bacteria develop antibiotic resistance through mechanisms like beta-lactamase production, a challenge since penicillin's discovery.
- Beta-lactamases hydrolyze beta-lactam antibiotics via serine attack or zinc-activated water molecules.
- Cefuroxime, a second-generation cephalosporin, exhibits enhanced stability against many beta-lactamases due to its unique structure.
Purpose of the Study:
- To review bacterial susceptibility to cefuroxime in Italy.
- To evaluate the clinical utility of cefuroxime in settings with beta-lactamase-producing bacteria.
Main Methods:
- Literature review of bacterial susceptibility data in Italy.
- Analysis of cefuroxime's efficacy against beta-lactamase-producing pathogens.
Main Results:
- Cefuroxime demonstrates efficacy against many clinically significant bacteria, including Haemophilus, Moraxella, Staphylococci, and Enterobacteriaceae.
- However, advanced enzymes like carbapenemases and extended-spectrum beta-lactamases can hydrolyze cefuroxime.
- The review confirms cefuroxime's continued therapeutic relevance in Italy.
Conclusions:
- Cefuroxime remains a valuable treatment option despite the prevalence of beta-lactamase-producing bacteria.
- Its stability and spectrum of activity support its use in various clinical scenarios.
- Ongoing monitoring of resistance patterns is crucial for optimizing antibiotic therapy.